Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2022 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALOGet Rating) issued an update on its FY 2022 earnings guidance on Wednesday morning. The company provided EPS guidance of $2.050-$2.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.180. The company issued revenue guidance of $530 million-$560 million, compared to the consensus revenue estimate of $553.27 million.

A number of brokerages recently issued reports on HALO. Piper Sandler dropped their price target on shares of Halozyme Therapeutics from $43.00 to $42.00 in a research note on Wednesday, February 23rd. StockNews.com upgraded shares of Halozyme Therapeutics from a hold rating to a buy rating in a research note on Monday. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a strong sell rating to a hold rating and set a $37.00 price target for the company in a research note on Monday, March 14th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus price target of $47.83.

Halozyme Therapeutics stock opened at $41.62 on Wednesday. Halozyme Therapeutics has a 1 year low of $31.36 and a 1 year high of $51.57. The firm’s 50-day moving average is $36.66 and its 200-day moving average is $36.85. The company has a debt-to-equity ratio of 4.00, a quick ratio of 7.45 and a current ratio of 7.91. The company has a market cap of $5.73 billion, a P/E ratio of 15.13 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last issued its earnings results on Tuesday, February 22nd. The biopharmaceutical company reported $0.39 EPS for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.04. The company had revenue of $102.00 million during the quarter, compared to the consensus estimate of $97.10 million. Halozyme Therapeutics had a return on equity of 164.68% and a net margin of 90.84%. As a group, sell-side analysts predict that Halozyme Therapeutics will post 1.99 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Silvercrest Asset Management Group LLC lifted its stake in Halozyme Therapeutics by 11.2% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 8,758 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 880 shares during the last quarter. Advisors Asset Management Inc. lifted its position in Halozyme Therapeutics by 5.6% in the 4th quarter. Advisors Asset Management Inc. now owns 27,978 shares of the biopharmaceutical company’s stock valued at $1,125,000 after purchasing an additional 1,486 shares during the last quarter. California State Teachers Retirement System lifted its position in Halozyme Therapeutics by 1.6% in the 4th quarter. California State Teachers Retirement System now owns 195,973 shares of the biopharmaceutical company’s stock valued at $7,880,000 after purchasing an additional 3,170 shares during the last quarter. Deutsche Bank AG boosted its stake in Halozyme Therapeutics by 6.3% during the 4th quarter. Deutsche Bank AG now owns 111,307 shares of the biopharmaceutical company’s stock valued at $4,476,000 after purchasing an additional 6,617 shares during the period. Finally, LPL Financial LLC grew its position in Halozyme Therapeutics by 42.0% in the 4th quarter. LPL Financial LLC now owns 24,589 shares of the biopharmaceutical company’s stock worth $989,000 after purchasing an additional 7,271 shares during the last quarter. 90.21% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile (Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Read More

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.